Clostridium difficile infection (CDI) is inflammation of the colon caused by a bacteria called clostridium difficile and is the most common cause of infectious diarrhea in hospitalized patients. Blood ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides difficile (C. diff) among adults given low-dose oral vancomycin during ...

Preventative oral vancomycin reduces the incidence of C. difficle during allogeneic hematopoietic stem cell transplantation, according to a study by Pittsburgh-based University of Pennsylvania ...

Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading antibiotic used to fight it ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research from ...

A study has linked initial vancomycin monotherapy to higher rates of Clostridium difficile infection in patients with inflammatory bowel disease, according to a report by Internal Medicine News. The ...

The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within ...

Fecal microbiota transplant might be considered for first-line treatment of Clostridioides difficile (C. diff), based on noninferiority findings from a randomized, open-label trial. A similar ...